DPP-4抑制剂。

文章的细节

引用

复制到剪贴板

Ahren B

DPP-4抑制剂。

最好Pract Res中国性金属底座。2007;12月21(4):517 - 33所示。doi: 10.1016 / j.beem.2007.07.005。

PubMed ID

18054733 (在PubMed

]

文摘

抑制dipeptidyl肽酶4 (DPP-4)是一种新型的治疗2型糖尿病。DPP-4抑制防止glucagon-like肽1 (GLP-1)的失活,从而增加GLP-1水平的活跃。这增加胰岛素分泌,降低胰高血糖素分泌,从而降低血糖水平。几个DPP-4抑制剂在临床的发展。迄今为止最有经验与sitagliptin(默克公司;FDA批准的)和vildagliptin(诺华;提起)。这些都是与长期口服活性化合物,允许每日一次。sitagliptin和vildagliptin改善2型糖尿病代谢控制,在单药治疗和联合二甲双胍和thiazolidinediones。减少HbA (1 c)的约1%是在研究DPP-4抑制的52周的持续时间。 DPP-4 inhibition is safe and well tolerated, the risk of hypoglycaemia is minimal, and DPP-4 inhibition is body-weight neutral. DPP-4 inhibition is suggested to be a first-line treatment of type-2 diabetes, particularly in its early stages in combination with metformin. However, the durability and long-term safety of DPP-4 inhibition remain to be established.

DrugBank数据引用了这篇文章

药物

Vildagliptin